News | October 30, 2022
Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
India will become a digital health leader, as we have the world’s best technical manpower required and our data is the cheapest in the world, approaching 100 percent coverage
The JUMP-CP Consortium’s aim is to validate and scale up image-based drug discovery strategies by creating the world’s largest public cell imaging data set
The team will also assist the state health departments in terms of public health measures, management guidelines and protocols to manage the increasing cases of Avian Influenza
The company has posted net profit of Rs. 13.21 crores for the period ended September 30, 2022
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Ketorolac Tromethamine Tablets are indicated to relieve moderately severe pain, usually after surgery.
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The company has received the Certificate of GMP Compliance from the representative European inspection authority, Health Products Regulatory Authority (HPRA), Ireland.
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 112 million in the U.S. (IQVIA MAT August 2022).
Subscribe To Our Newsletter & Stay Updated
